Literature DB >> 24618611

Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression.

Robert S Ohgami1, Anoop K Sendamarai, Susan K Atwater, Michaela Liedtke, Mark D Fleming, Yasodha Natkunam, Roger A Warnke.   

Abstract

Although indolent T-lymphoblastic proliferations (iT-LBP) are rare, this diagnosis should be excluded in any patient with an extrathymic proliferation of immature TdT+T cells. Unlike T-lymphoblastic leukemia/lymphoma, patients with iT-LBP do not require chemotherapy. We report a case of iT-LBP with disseminated multinodal involvement in an otherwise healthy 49-year-old woman. Multiple lymph node biopsies were performed over the course of several months demonstrating persistent and anatomically diffuse involvement. Over 18 months, and without therapy, she has remained healthy, and her lymphadenopathy significantly improved. No bone marrow or peripheral blood involvement was ever identified. Atypical T cells showed an immunophenotypic spectrum of T-cell antigen expression with partial CD33 on a subset of T cells detected by both flow cytometry and immunohistochemistry. Both T-cell clonality and Human Androgen Receptor Assay (HUMARA) studies, performed on lymph node biopsy specimens, were negative. This case represents the first detailed clinical, morphologic, molecular, and immunophenotypic description of disseminated multinodal involvement by nonclonal iT-LBP with partial CD33 expression on T cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24618611     DOI: 10.1097/PAS.0000000000000197

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Hepatic carcinoma with indolent T-lymphoblastic proliferation (iT-LBP).

Authors:  Mei Kong; Zhaoming Wang; Xiaodong Teng; Liming Xu; Jiming Liu; Chaozhe Jiang; Lisong Teng
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

2.  Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Authors:  Alexandra Nagy; Aparna Bhaduri; Nahid Shahmarvand; Jahanbanoo Shahryari; James L Zehnder; Roger A Warnke; Tariq Mughal; Siraj Ali; Robert S Ohgami
Journal:  Blood Adv       Date:  2018-03-13

3.  Indolent T-lymphblastic proliferation: report of a case involving the upper aerodigestive tract.

Authors:  Fang Yang; Tengfei Liu; Haiyan Zhao; Zhiyan Hu; Liwei Xiao; Yanping Liu; Xiaoyan Wang; Zuguo Li
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

4.  Indolent T-lymphoblastic proliferation: a report of three cases.

Authors:  Zheng Yuanyuan; Xie Jianlan; Zhang Yanlin; Zhou Xiaoge
Journal:  Virchows Arch       Date:  2021-09-04       Impact factor: 4.064

5.  TdT+ T-Lymphoblastic Proliferation in Castleman Disease.

Authors:  Chang Gok Woo; Jooryung Huh
Journal:  J Pathol Transl Med       Date:  2015-01-15

6.  Sirolimus for the Treatment of Airway Obstruction due to Indolent T-Lymphoblastic Proliferation.

Authors:  Eric Moughames; Ana P Kiess; Lee M Akst; Antoine Azar
Journal:  Case Reports Immunol       Date:  2019-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.